Trial reportNeuro-oncology2024
[Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.
Trial report in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04081701 (68Ga), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.Neuro-oncology · 2025Pooled it
- Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026Review
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances.Current oncology reports · 2026Review
- Imaging Biomarkers in Radiotherapy.Cancers · 2026Review
- Yttrium-90 radioembolization for treatment of anaplastic meningioma liver metastases.Radiology case reports · 2026Article
- Molecular Imaging in Photon Radiotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- SUV-max ofJournal of neuro-oncology · 2025Article
- The Rationale for Early Adjuvant Radiotherapy After Gross Total Resection of Atypical Meningioma.Neurosurgery · 2025Article
- SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.Journal of neuropathology and experimental neurology · 2025Article
- An Update on DOTA-Peptides PET Imaging and Potential Advancements of Radioligand Therapy in Intracranial Meningiomas.Life (Basel, Switzerland) · 2025Review
- Preoperative PET/MRI and radio-guided surgery using [Cu64]DOTATATE in meningioma: a feasibility study. Illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
- Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.AJNR. American journal of neuroradiology · 2025Review
- Long-term outcomes of active surveillance after DOTATATE PET/MRI-confirmed gross total resection in WHO grade 2 meningioma.Neuro-oncology advancesArticle
- Prostate specific membrane antigen (PSMA) PET/CT for radiation planning and response assessment in intracranial high-grade gliomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundOur purpose was to determine the utility of [68Ga]-DOTATATE PET/MRI in meningioma response assessment following radiosurgery.
methodsPatients with meningioma prospectively underwent postoperative DOTATATE PET/MRI. Co-registered PET and gadolinium-enhanced T1-weighted MRI were employed for radiosurgery planning. Follow-up DOTATATE PET/MRI was performed at 6-12 months post-radiosurgery. Maximum absolute standardized uptake value (SUV) and SUV ratio (SUVRSSS) referencing superior sagittal sinus (SSS) blood pool were obtained. Size change was determined by Response Assessment in Neuro-Oncology (RANO) criteria. Association of SUVRSSS change magnitude and progression-free survival (PFS) was evaluated using Cox regression.
resultsTwenty-seven patients with 64 tumors (26% World Health Organization [WHO]-1, 41% WHO-2, 26% WHO-3, and 7% WHO-unknown) were prospectively followed post stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT; mean dose: 30 Gy, modal dose 35 Gy, mean of 5 fractions). Post-irradiation SUV and SUVRSSS decreased by 37.4% and 44.4%, respectively (P < .0001). Size product decreased by 8.9%, thus failing to reach the 25% significance threshold as determined by RANO guidelines. Mean follow-up time was 26 months (range: 6-44). Overall mean PFS was 83% and 100%/100%/54% in WHO-1/-2/-3 subcohorts, respectively, at 34 months. At maximum follow-up (42-44 months), PFS was 100%/83%/54% in WHO-1/-2/-3 subcohorts, respectively. Cox regression analyses revealed a hazard ratio of 0.48 for 10-unit reduction in SUVRSSS in the SRS cohort.
conclusionsDOTATATE PET SUV and SUVRSSS demonstrated marked, significant decrease post-radiosurgery. Lesion size decrease was statistically significant; however, it was not clinically significant by RANO criteria. DOTATATE PET/MR thus represents a promising imaging biomarker for response assessment in meningiomas treated with radiosurgery. CLINICALTRIALS.GOV IDENTIFIER: NCT04081701.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.